Credo Technology Group Holding Ltd vs Stryker Corporation — how do they compare? Credo Technology Group Holding Ltd trades at $216.28 (market cap $39.82B), while Stryker Corporation trades at $277.34 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 2.7× Credo Technology Group Holding Ltd's market cap, and Stryker Corporation pays a 1.27% dividend while Credo Technology Group Holding Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Credo Technology Group Holding Ltd for 22 Days and Stryker Corporation for 21 Days on average.
| CRDO | SYK | |
|---|---|---|
Market Cap | $39.82B | $106.24B |
Volume | 9,451,558 | 2,982,001 |
Sector | Technology | Health |
52-Week High | $302.52 | $388.35 |
52-Week Low | $87.81 | $269.75 |
Typical Hold Time | 22 Days | 21 Days |
Enterprise Value | $39.08B | $117.70B |
Dividend Yield | — | 1.27% |
Signals from Pluang's Aura AI — not financial advice
CRDO trades at $216.55, down 1.57% on the day, but maintains strong bullish momentum with triple-digit revenue growth driven by AI infrastructure demand. The stock shows robust fundamentals with 33.83% net margins and consistent earnings beats, though valuation metrics remain elevated with a P/E of 74.6. Technical indicators suggest bullish momentum with support at $204 and resistance at $222.
Outlook remains positive given explosive AI-driven growth and strong analyst support (87.5% buy ratings), but premium valuation and customer concentration present execution risks. The consensus price target of $267.33 implies 23% upside potential from current levels, supported by expanding optical product offerings and hyperscaler relationships.
Stryker (SYK) trades at $277.52, up 0.77% today, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279. Fundamentally, the company reported strong profitability with a 14.43% net income margin in 2026 and beat EPS estimates in two of the last three quarters. However, recent news highlights potential legal and manufacturing issues that have pressured investor sentiment.
The outlook is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities lie in SYK's robust earnings growth and market leadership in medical technology, but risks include ongoing legal investigations and persistent manufacturing challenges that could impact future performance.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →